日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance

SHIELD 研究：一项多中心、开放标签、单臂试验，旨在评估福斯特沙韦联合优化背景疗法 (OBT) 在对当前联合抗逆转录病毒疗法 (cART) 治疗失败且存在双重或三重抗逆转录病毒 (ARV) 耐药性的 HIV 感染儿童和青少年中的安全性、药代动力学和抗病毒活性。

期刊:BMC Infectious Diseases
影响因子:3
doi:10.1186/s12879-026-12806-9
Grasa, Carlos; Salvadori, Nicolas; Nardone, Alessandra; Than-In-At, Kanchana; Koblansky, Alicia; Parry, Chris; Thakkar, Nilay; Wang, Marcia; Giaquinto, Carlo; Rojo, Pablo; Cressey, Tim R
HIV
炎症/感染
微生物学
发表日期：2026
文献求助 收藏

Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

在未感染 HIV 的成年人中，口服新型 HIV-1 衣壳抑制剂 VH4011499 的临床药代动力学和安全性研究

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-025-01129-y
Thakkar, Nilay; Griesel, Rulan; Pierce, Amy; Bainbridge, Veronica; Shepherd, Bronagh; Angelis, Konstantinos; Tomlinson, Andrew; Gandhi, Yash; Brimhall, Darin; Spears, Brian; Anderson, Daijha; Pinnick, Emma; Acuipil, Carolina; McCoig, Cynthia; Baker, Mark; Benn, Paul
HIV
炎症/感染
微生物学
发表日期：2025
文献求助 收藏

Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV

新型 HIV-1 衣壳抑制剂 VH4004280 在非 HIV 感染成人口服给药后的临床药代动力学和安全性研究

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-025-01154-x
Thakkar, Nilay; Griesel, Rulan; Pierce, Amy; Bainbridge, Veronica; Shepherd, Bronagh; Angelis, Konstantinos; Tomlinson, Andrew; Gandhi, Yash; Brimhall, Darin; Anderson, Daijha; Andrews, Susan; Acuipil, Carolina; McCoig, Cynthia; Baker, Mark; Benn, Paul
HIV
炎症/感染
微生物学
发表日期：2025
文献求助 收藏

Population pharmacokinetics and exposure-response relationship for temsavir following fostemsavir administration in treatment-experienced HIV patients

在接受过治疗的 HIV 患者中，福斯特沙韦给药后替姆沙韦的群体药代动力学和暴露-反应关系

期刊:Pharmacology Research & Perspectives
影响因子:
doi:10.1002/prp2.70023
Parasrampuria, Ridhi; Thakkar, Nilay; Moore, Katy; Ackerman, Peter; Magee, Mindy
HIV
微生物学
发表日期：2025
文献求助 收藏

Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy

建立基于生理学的福斯特沙韦药代动力学模型及其在孕期给药指导中的关键应用

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.13156
Salem, Farzaneh; Nguyen, Dung; Bush, Mark; Moore, Katy P; Mudunuru, Jennypher; Stamatopoulos, Konstantinos; Thakkar, Nilay; Taskar, Kunal S
发表日期：2024
文献求助 收藏

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants

在健康受试者中，替姆沙韦（HIV-1 附着抑制剂前药福司沙韦的活性成分）与考比司他、依曲韦林、达芦那韦/考比司他或达芦那韦/利托那韦（含或不含依曲韦林）联合用药的药代动力学研究

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.02251-21
Moore, Katy; Thakkar, Nilay; Magee, Mindy; Sevinsky, Heather; Vakkalagadda, Blisse; Lubin, Susan; Llamoso, Cyril; Ackerman, Peter
HIV
微生物学
发表日期：2022
文献求助 收藏

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial

新型抗疟药他非诺喹的群体药代动力学

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/AAC.00711-18
Thakkar, Nilay; Green, Justin A; Koh, Gavin C K W; Duparc, Stephan; Tenero, David; Goyal, Navin
发表日期：2018
文献求助 收藏

Clinical Pharmacology Studies in Critically Ill Children

危重儿童的临床药理学研究

期刊:Pharmaceutical Research
影响因子:4.3
doi:10.1007/s11095-016-2033-y
Thakkar, Nilay; Salerno, Sara; Hornik, Christoph P; Gonzalez, Daniel
发表日期：2017
文献求助 收藏

Effect of Liver Disease on Hepatic Transporter Expression and Function.

肝脏疾病对肝脏转运蛋白表达和功能的影响

期刊:Journal of Pharmaceutical Sciences
影响因子:3.8
doi:10.1016/j.xphs.2017.04.053
Thakkar Nilay, Slizgi Jason R, Brouwer Kim L R
免疫/内分泌
发表日期：2017
文献求助 收藏

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia

Lambert-Eaton 重症肌无力患者中 3,4-二氨基吡啶游离碱的群体药代动力学/药效学

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12218
Thakkar, Nilay; Guptill, Jeffrey T; Aleš, Kathy; Jacobus, David; Jacobus, Laura; Peloquin, Charles; Cohen-Wolkowiez, Michael; Gonzalez, Daniel
重症肌无力
免疫/内分泌
发表日期：2017
文献求助 收藏